Pentraxin-3 Is a Strong Biomarker of Sepsis Severity Identification and Predictor of 90-Day Mortality in Intensive Care Units Via Sepsis 3.0 Definitions

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Oct 23

PMID 34679604

Citations 10

Authors

Huan Chen

Tao Li

Shanshan Yan

Meidong Liu

Ke Liu

Huali Zhang

Min Gao

Xianzhong Xiao

Affiliations

Soon will be listed here.

Abstract

Background: Sepsis is the leading cause of mortality in intensive care units (ICUs). However, early diagnosis and prognosis of sepsis and septic shock are still a great challenge. Pentraxin-3 (PTX3) was shown to be associated with the severity and outcome of sepsis and septic shock. This study was carried out to investigate the diagnostic and prognostic value of PTX3 in patients with sepsis and septic shock based on Sepsis 3.0 definitions.

Methods: In this single-center prospective observational study, all patients' serum was collected for biomarker measurements within 24 h after admission. Logistic and Cox regression analyses were used to identify the potential biomarkers of diagnosis, severity stratification, and prediction.

Results: Serum levels of PTX3 were significantly increased on the first day of ICU admission, while septic shock patients had highest PTX3 levels than other groups. A combination between PTX3 and procalcitonin (PCT) could better discriminate sepsis and septic shock, and PTX3 was an independent predictor of mortality in sepsis and septic shock patients.

Conclusion: PTX3 may be a robust biomarker to classify the disease severity and predict the 90-day mortality of sepsis and septic shock based on the latest Sepsis 3.0 definitions.

Citing Articles

Pentraxin-3 as a novel prognostic biomarker in non-neutropenic invasive pulmonary aspergillosis patients.

Sun C, Cai X, Zhong H, Lu Y, Li Y, Cai Y Microbiol Spectr. 2025; 13(3):e0294524.

PMID: 39878524 PMC: 11878064. DOI: 10.1128/spectrum.02945-24.

Progress in the study of pentraxin-3(PTX-3) as a biomarker for sepsis.

Zhang Y, Li X, Zhang X, Wang T, Zhang X Front Med (Lausanne). 2024; 11:1398024.

PMID: 39021820 PMC: 11251883. DOI: 10.3389/fmed.2024.1398024.

Resistin as a potential diagnostic biomarker for sepsis: insights from DIA and ELISA analyses.

Lan Y, Guo W, Chen W, Chen M, Li S Clin Proteomics. 2024; 21(1):46.

PMID: 38951753 PMC: 11218185. DOI: 10.1186/s12014-024-09498-1.

Immunosuppression in Sepsis: Biomarkers and Specialized Pro-Resolving Mediators.

Padovani C, Yin K Biomedicines. 2024; 12(1).

PMID: 38255280 PMC: 10813323. DOI: 10.3390/biomedicines12010175.

The Predictive Value of Heparin-Binding Protein and D-Dimer in Patients with Sepsis.

Tang J, Yuan H, Wu Y, Fu S, Pan X Int J Gen Med. 2023; 16:2295-2303.

PMID: 37304904 PMC: 10257474. DOI: 10.2147/IJGM.S409328.

References

Song J, Moon S, Park D, Cho H, Kim J, Park J . Biomarker combination and SOFA score for the prediction of mortality in sepsis and septic shock: A prospective observational study according to the Sepsis-3 definitions. Medicine (Baltimore). 2020; 99(22):e20495. DOI: 10.1097/MD.0000000000020495. View

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Brunetta E, Folci M, Bottazzi B, De Santis M, Gritti G, Protti A . Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol. 2020; 22(1):19-24. DOI: 10.1038/s41590-020-00832-x. View

Calis J, van Woensel J, Lemson J . Severe sepsis and septic shock. N Engl J Med. 2013; 369(21):2062. DOI: 10.1056/NEJMc1312359. View

Coopersmith C, De Backer D, Deutschman C, Ferrer R, Lat I, Machado F . Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med. 2018; 44(9):1400-1426. PMC: 7095388. DOI: 10.1007/s00134-018-5175-z. View

Bottazzi B, Doni A, Garlanda C, Mantovani A . An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2009; 28:157-83. DOI: 10.1146/annurev-immunol-030409-101305. View

Bastrup-Birk S, Munthe-Fog L, Skjoedt M, Ma Y, Nielsen H, Kober L . Pentraxin-3 level at admission is a strong predictor of short-term mortality in a community-based hospital setting. J Intern Med. 2014; 277(5):562-72. DOI: 10.1111/joim.12294. View

Lundberg O, Lengquist M, Spangfors M, Annborn M, Bergmann D, Schulte J . Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit Care. 2020; 24(1):636. PMC: 7641835. DOI: 10.1186/s13054-020-03351-1. View

Hansen C, Bayarri-Olmos R, Kristensen M, Pilely K, Hellemann D, Garred P . Complement related pattern recognition molecules as markers of short-term mortality in intensive care patients. J Infect. 2020; 80(4):378-387. DOI: 10.1016/j.jinf.2020.01.010. View

10.

Lee Y, Gong M, Chau A, Wong W, Bazoukis G, Wong S . Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis. J Infect. 2017; 76(1):1-10. DOI: 10.1016/j.jinf.2017.10.016. View

11.

Rhee C, Jones T, Hamad Y, Pande A, Varon J, OBrien C . Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals. JAMA Netw Open. 2019; 2(2):e187571. PMC: 6484603. DOI: 10.1001/jamanetworkopen.2018.7571. View

12.

Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A . PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer. Physiol Rev. 2018; 98(2):623-639. PMC: 5985957. DOI: 10.1152/physrev.00016.2017. View

13.

Wong H, Cvijanovich N, Hall M, Allen G, Thomas N, Freishtat R . Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care. 2012; 16(5):R213. PMC: 3682317. DOI: 10.1186/cc11847. View

14.

Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I . Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 2010; 36(4):621-9. DOI: 10.1007/s00134-010-1752-5. View

15.

Ramirez G, Rovere-Querini P, Blasi M, Sartorelli S, Di Chio M, Baldini M . PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases. Front Immunol. 2019; 10:1135. PMC: 6548810. DOI: 10.3389/fimmu.2019.01135. View

16.

Uusitalo-Seppala R, Huttunen R, Aittoniemi J, Koskinen P, Leino A, Vahlberg T . Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS One. 2013; 8(1):e53661. PMC: 3544919. DOI: 10.1371/journal.pone.0053661. View

17.

Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

18.

Chen H, Li J, Yan S, Sun H, Tan C, Liu M . Identification of pathogen(s) in infectious diseases using shotgun metagenomic sequencing and conventional culture: a comparative study. PeerJ. 2021; 9:e11699. PMC: 8253115. DOI: 10.7717/peerj.11699. View

19.

Longhitano Y, Zanza C, Thangathurai D, Taurone S, Kozel D, Racca F . Gut Alterations in Septic Patients: A Biochemical Literature Review. Rev Recent Clin Trials. 2020; 15(4):289-297. DOI: 10.2174/1574887115666200811105251. View

20.

Mjelva O, Ponitz V, Brugger-Andersen T, Grundt H, Staines H, Nilsen D . Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome. Eur J Prev Cardiol. 2015; 23(11):1130-40. DOI: 10.1177/2047487315619733. View